Elsevier Is Re-Launching "Embase" To Be A Powerful Resource Providing Deep Insights And Answers To Biomedical Researchers
Amsterdam, 30 November 2009 - Elsevier, the world’s leading publisher of scientific, medical and technical products and services, today announced a major re-launch of Embase, its comprehensive biomedical database which holds over 20 million indexed records from more than 7,000 active, peer reviewed journals.
Embase has long played a key role in the advancement of new biomedical and pharmaceutical insights. Now, new developments and updates include:
• Enabling all biomedical researchers to use Embase -- extending its “usability” from information specialists to also include all biomedical and pharmaceutical scientists, and clinical and regulatory professionals.
• New retrieval tools that further drive discovery, including quick and easy refining of search results and the display of indexed drug-drug and drug-disease relations.
• Improved comprehensiveness through the addition of indexed articles-in-press and conference abstracts.
• To signify the enhanced focus on biomedical answers, the product has a new, fresh look and feel to it.
Thomas Gutjahr, Head of the Knowledge Center at Actelion Pharmaceuticals Ltd., comments: “I’m very impressed by all the new improvements which I believe will greatly help with pin-pointing certain searches, e.g. drug-drug interactions or drug-disease searches.”
Embase supports researchers with key tasks such as tracking of drug adverse events, comparing drug therapies, and Evidence Based Medicine research. It provides researchers with deep insights and understanding from the world’s life sciences information, enabling effective discoveries towards medical discovery and treatment.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. www.elsevier.com